Mahmoud Hala A, El Amin Hussein Ahmed, Ahmed Ehab Saleh Mahmoud, Kenawy Ahmed Gaber, El-Ebidi Abdallah M, ElNakeeb Islam, Kholef Emad Farah Mohammed, Elsewify Wael Abd Elgwad
Department of Internal Medicine, Faculty of Medicine, Aswan University, Aswan, Egypt.
Department of Internal Medicine, Faculty of Medicine, Assiut University, Assiut, Egypt.
Int J Gen Med. 2022 Mar 25;15:3281-3291. doi: 10.2147/IJGM.S353244. eCollection 2022.
Colorectal cancer is a common and lethal disease. It is estimated that approximately 145,600 new cases of large bowel cancer are diagnosed annually in the USA. MiRNA-223 and miRNA-182 have been reported in various cancers, such as lung, gastric, breast and colorectal cancer and proposed to be valid and reliable for diagnosis as well as prognosis.
This study aimed to determine the role of miR-223 and miR-182 as novel biomarkers for early detection and prognosis of CRC.
This case-control study was conducted at the department of Internal Medicine, Aswan University Hospital, in the period from the 1st of February 2020 to the 20th of April 2021. Thirty-five cases and thirty age- and sex-matched controls were included in the study. All patients were subject to complete clinical evaluation, routine investigations, occult blood in stool, serum levels of CEA and CA 19-9, serum levels of miR-223 and miR-182 by quantitative PCR.
Significant difference between the two studied groups regarding biomarker changes was found. ROC curve analysis showed that the new markers had excellent diagnostic as well as prognostic criteria. Micro-RNA-223 diagnostic accuracy, sensitivity, specificity, PPV, NPV, FDR and FOR were 97%, 97.1%, 96.7%, 97%, 97%, 3.3% and 2.9%, respectively. Also, micro-RNA-182 diagnostic accuracy, sensitivity, specificity, PPV, NPV, FDR and FOR were 97%, 98%, 96%, 96%, 98%, 3.9% and 2%, respectively.
MiR-223 and miR-182 have been discovered to be relevant and reliable biomarkers for the early identification and prognosis of CRC. Increased levels of miR-223 and miR-182 were associated with increased risk of disease progression, and the more accurate the value of miR-223 and miR-182, the earlier the diagnosis of colorectal cancer.
结直肠癌是一种常见的致命疾病。据估计，美国每年约有145,600例新的大肠癌病例被诊断出来。miRNA - 223和miRNA - 182已在多种癌症中被报道，如肺癌、胃癌、乳腺癌和结直肠癌，并被认为对诊断和预后有效且可靠。
本研究旨在确定miR - 223和miR - 182作为结直肠癌早期检测和预后的新型生物标志物的作用。
本病例对照研究于2020年2月1日至2021年4月20日在阿斯旺大学医院内科进行。研究纳入了35例病例和30例年龄及性别匹配的对照。所有患者均接受了全面的临床评估、常规检查、粪便潜血检查、血清癌胚抗原（CEA）和糖类抗原19 - 9（CA 19 - 9）水平检测以及通过定量PCR检测血清miR - 223和miR - 182水平。
发现两个研究组在生物标志物变化方面存在显著差异。ROC曲线分析表明，新标志物具有出色的诊断和预后标准。微小RNA - 223的诊断准确性、敏感性、特异性、阳性预测值（PPV）、阴性预测值（NPV）、假发现率（FDR）和错误发现率（FOR）分别为97%、97.1%、96.7%、97%、97%、3.3%和2.9%。此外，微小RNA - 182的诊断准确性、敏感性、特异性、PPV、NPV、FDR和FOR分别为97%、98%、96%、96%、98%、3.9%和2%。
已发现miR - 223和miR - 182是结直肠癌早期识别和预后的相关且可靠的生物标志物。miR - 223和miR - 182水平升高与疾病进展风险增加相关，且miR - 223和miR - 182的值越准确，结直肠癌的诊断越早。
